Arctic Bioscience AS (ABS.OL)
NOK 1.9
(-5.0%)
NOK 1.9
(-5.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -40.28 Million | -25.39 Million | -39.49 Million | -21.88 Million | 2.15 Million |
| Net Income | -45.51 Million | -34.02 Million | -42.57 Million | -22.59 Million | -3.98 Million |
| Depreciation & Amortization | 5.38 Million | 3.73 Million | 2.51 Million | 1.19 Million | 1.07 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -154.3 Thousand | 4.89 Million | 568.79 Thousand | -490.6 Thousand | - |
| Other non-cash items | 4.06 Million | -1.00 | 5.58 Million | -1.00 | 5.06 Million |
| Investing Cash Flow | -43.1 Million | -58.56 Million | -36.5 Million | -13.43 Million | - |
| Investments in PPE | -45.33 Million | -58.56 Million | -36.5 Million | -13.43 Million | - |
| Acquisitions | 2.23 Million | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | 2.23 Million | - | - | - | - |
| Financing Cash Flow | 18.84 Million | 749.99 Thousand | 290.75 Million | 23.92 Million | - |
| Debt repayment | -2.04 Million | - | -6.57 Million | -582.93 Thousand | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 16.79 Million | 749.99 Thousand | 299.2 Million | 22.63 Million | - |
| Other Financing Activities | 16.79 Million | - | -1.87 Million | 1.87 Million | - |
| Accounts receivables | 3.9 Million | -5.77 Million | 3.3 Million | - | - |
| Accounts payables | 122.56 Thousand | 9.89 Million | -1.57 Million | - | - |
| Inventory | 2.66 Million | -6.93 Million | -2.27 Million | -8.78 Million | - |
| Other working capital | -6.85 Million | 7.71 Million | 1.11 Million | 8.29 Million | - |
| Cash at beginning of period | 144.15 Million | 227.36 Million | 12.6 Million | 23.99 Million | 811.54 Thousand |
| Cash at end of period | 79.6 Million | 144.15 Million | 227.36 Million | 12.6 Million | 23.96 Million |
| Capital Expenditure | -45.33 Million | -58.56 Million | -36.5 Million | -13.43 Million | - |
| Effect of forex changes on cash | 427.00 | - | - | - | - |
| Net cash flow / Change in cash | -64.54 Million | -83.21 Million | 214.76 Million | -11.39 Million | 23.15 Million |
| Free Cash Flow | -85.62 Million | -83.96 Million | -75.99 Million | -35.32 Million | 2.15 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -11.75 Million | -11.75 Million | -45.51 Million | -12.42 Million | -12.42 Million | - |
| Depreciation & Amortization | 1.28 Million | 1.28 Million | 5.38 Million | 1.41 Million | 1.41 Million | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.77 Million | -2.77 Million | -154.3 Thousand | 2.51 Million | 2.51 Million | - |
| Other non-cash items | 444.95 Thousand | 444.95 Thousand | 4.06 Million | 2.21 Million | 2.21 Million | - |
| Investing Cash Flow | -16.97 Million | -16.97 Million | -43.1 Million | -9.74 Million | -9.74 Million | - |
| Investments in PPE | -76.83 Thousand | -76.83 Thousand | -45.33 Million | -10.86 Million | -10.86 Million | - |
| Acquisitions | - | - | 2.23 Million | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -16.89 Million | -16.89 Million | - | 1.11 Million | 1.11 Million | - |
| Financing Cash Flow | -114.6 Thousand | -114.6 Thousand | 18.84 Million | -1.07 Million | -1.07 Million | - |
| Debt repayment | - | - | -2.04 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 16.79 Million | - | - | - |
| Other Financing Activities | -114.6 Thousand | -114.6 Thousand | - | -1.07 Million | -1.07 Million | - |
| Accounts receivables | -901.22 Thousand | -901.22 Thousand | 3.9 Million | 3.5 Million | 3.5 Million | - |
| Accounts payables | - | - | 122.56 Thousand | - | - | - |
| Inventory | 1.08 Million | 1.08 Million | 2.66 Million | 1.28 Million | 1.28 Million | - |
| Other working capital | -2.95 Million | -2.95 Million | -6.85 Million | -2.27 Million | -2.27 Million | - |
| Cash at beginning of period | - | - | 144.15 Million | - | 113.8 Million | 130.6 Million |
| Cash at end of period | -29.88 Million | -29.88 Million | 79.6 Million | -17.1 Million | 96.7 Million | 130.6 Million |
| Capital Expenditure | -76.83 Thousand | -76.83 Thousand | -45.33 Million | -10.86 Million | -10.86 Million | - |
| Effect of forex changes on cash | - | - | 427.00 | - | - | - |
| Net cash flow / Change in cash | -29.88 Million | -29.88 Million | -64.54 Million | -17.1 Million | -17.1 Million | - |
| Free Cash Flow | -12.87 Million | -12.87 Million | -85.62 Million | -17.14 Million | -17.14 Million | - |
6390
GRGCF
PEA
000590
GUJCRED
ECN